Cas:52918-86-2 1,4-dibromoadamantane manufacturer & supplier

Chemical Name:1,4-dibromoadamantane

CAS.NO:52918-86-2

Synonyms:1,4-dibromoadamantane,mixture of cis and tr

Molecular Formula:C₁₀H₁₄Br₂

Molecular Weight:294.02600

HS Code:2903890090

Physical and Chemical Properties:

Melting point:95-98ºC(lit.)

Boiling point:295.8ºC at 760 mmHg

Density:1.804 g/cm3

Index of Refraction:1.626

PSA:

Exact Mass:291.94600

LogP:3.72350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,4-dibromoadamantane,mixture of cis and tr chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-dibromoadamantane,mixture of cis and tr physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-dibromoadamantane,mixture of cis and tr Use and application,1,4-dibromoadamantane,mixture of cis and tr technical grade,usp/ep/jp grade.

Related News: As part of the strategy, the government will review the research funding offer to retain, attract and support the very best researchers, innovators and their teams. 3-bromophenoxathiin manufacturers Wavelength’s growth in the API space comes as nations around the world look to develop redundant supply chains for key generic medicines amid the pandemic. Pentanedioic acid bis-(hydroxy-p-tolyl-amide) suppliers An inherent advantage of using enzymes for synthetic chemistry is that they increase regio-, enantio-, and stereoselectivity for more efficient conversion of substrate to product. 2,4,6-trimethyl-5-methoxymethoxy-cycloheptanone vendor & factory Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. ,Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA.